Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 2/20 | 0.47 |
| ▸ | LATS1 | O95835 | 3/20 | 0.36 |
| ▸ | LATS2 | Q9NRM7 | 3/20 | 0.36 |
| ▸ | CHUK | O15111 | 1/20 | 0.35 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.34 |
| ▸ | CHKA | P35790 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | HTR6 | P50406 | 3/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8440409 | 0.83 | CYP2A6 (0.43) | CYP2A6LATS1LATS2CHRM5CHKA | |
| SCHEMBL30940059 | 0.76 | CYP2A6 (0.53) | CYP2A6CHUKSMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL3962397 | 0.76 | CYP2A6 (0.53) | CYP2A6CHUKSMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL8440389 | 0.76 | CYP2A6 (0.40) | CYP2A6LATS1LATS2CHRM5CHKA | |
| SCHEMBL14438020 | 0.75 | CYP2A6 (0.51) | CYP2A6SMN1; SMN2ALDH1A1RAB9A | |
| SCHEMBL8438931 | 0.74 | CYP2A6 (0.41) | CYP2A6LATS1LATS2HTR6 | |
| SCHEMBL8442574 | 0.74 | CYP2A6 (0.41) | CYP2A6CHRM5CHKASMN1; SMN2ALDH1A1 | |
| SCHEMBL9312651 | 0.72 | MAPT (0.48) | CYP2A6SMN1; SMN2MAPTALDH1A1RAB9A | |
| SCHEMBL8440769 | 0.72 | LATS1 (0.38) | CYP2A6LATS1LATS2MAPTHTR6 | |
| SCHEMBL25030031 | 0.71 | HTR6 (0.52) | CYP2A6HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025264954-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMACEUTICALS, INC. (US) | 2025-12-26 | — | — | WO | disclosed |